Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus paracasei inm25-Lpc is a specific strain of *Lactobacillus paracasei*, a Gram-positive, heterofermentative lactic acid bacterium commonly found in the human intestinal tract, mouth, and various fermented foods and dairy products. As a probiotic, it is believed to contribute to gut health by modulating the gut microbiota, enhancing gut barrier function, and exerting immunomodulatory and anti-inflammatory effects. While specific details for the inm25-Lpc strain are not widely published, *Lactobacillus paracasei* in general is known to produce inhibitory compounds against pathogens, compete for adhesion sites and nutrients, and influence cholesterol metabolism. It is often utilized in dietary supplements and functional foods for its potential benefits in areas such as immune support, digestive health, and alleviation of conditions like hay fever and eczema. The species *Lactobacillus paracasei* was reclassified to *Lacticaseibacillus paracasei* in April 2020.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lactobacillus paracasei inm25-Lpc.